Cargando…

In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells

BACKGROUND: Acute Myeloid Leukemia (AML) is a malignancy of myeloid precursor cells that arise from genomic alterations in the expression of key growth regulatory genes causing cells to assume an undifferentiated state and continue to proliferate. Recent efforts have focused on developing therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montoya, Justin J., Turnidge, Megan A., Wai, Daniel H., Patel, Apurvi R., Lee, David W., Gokhale, Vijay, Hurley, Laurence H., Arceci, Robert J., Wetmore, Cynthia, Azorsa, David O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935221/ https://www.ncbi.nlm.nih.gov/pubmed/31881855 http://dx.doi.org/10.1186/s12885-019-6464-9

Ejemplares similares

Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene
por: Guo, Kexiao, et al.
Publicado: (2008)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
por: Bista, Ranjan, et al.
Publicado: (2017)

Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4
por: Qin, Yong, et al.
Publicado: (2007)

Quindoline-derivatives display potent G-quadruplex-mediated antiviral activity against herpes simplex virus 1
por: Frasson, Ilaria, et al.
Publicado: (2022)

Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex
por: Miranti, Cindy K., et al.
Publicado: (2020)

Correction: Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex
por: Miranti, Cindy K., et al.
Publicado: (2020)

Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X
por: Weldon, Carika, et al.
Publicado: (2018)

Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
por: Lee, Anbok, et al.
Publicado: (2021)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin
por: Sierra-Ramirez, Arantzazu, et al.
Publicado: (2020)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
por: Mohamad Anuar, Nur Najmi, et al.
Publicado: (2020)

Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
por: González‐Gualda, Estela, et al.
Publicado: (2020)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro
por: Chteinberg, Emil, et al.
Publicado: (2020)

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021)

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
por: van Beek, Jasper J. P., et al.
Publicado: (2016)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation
por: Hernández-Silva, David, et al.
Publicado: (2022)

Pharmacological interactions: Synergism, or not synergism, that is the question
por: Calzetta, Luigino, et al.
Publicado: (2021)

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
por: Kour, Smit, et al.
Publicado: (2019)

Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic
por: Henriques, Ana C., et al.
Publicado: (2021)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
por: Softah, Abrar, et al.
Publicado: (2023)

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region
por: Dai, Jixun, et al.
Publicado: (2006)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors
por: Zhu, Yi, et al.
Publicado: (2016)

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis
por: Yang, Hao, et al.
Publicado: (2020)

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence
por: Nor Hisam, Nur Syahidah, et al.
Publicado: (2021)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
por: Pullarkat, V., et al.
Publicado: (2022)

Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides
por: Almaaytah, Ammar, et al.
Publicado: (2018)

Identification of G-quadruplexes in long functional RNAs using 7-deaza-Guanine RNA
por: Weldon, Carika, et al.
Publicado: (2016)

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
por: Sharma, Anuj K., et al.
Publicado: (2020)

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
por: Harrison, Claire N., et al.
Publicado: (2022)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ltlim52gbcs8p61roat12lvr26